Results 201 to 210 of about 6,286,028 (355)

How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU

British Journal of Clinical Pharmacology, EarlyView.
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley   +1 more source

Association Between Intra-Articular Hyaluronic Acid Injections and Reduction in Analgesic Prescriptions in Knee Osteoarthritis: A Real-World Study from German Outpatient Care. [PDF]

J Clin Med
Kostev K, Konrad M, Tanislav C.
europepmc   +1 more source

A Novel Intelligence Recommendation Model for Insurance Products with Consumer Segmentation

, 2014
Wei Xu, Jiajia Wang, Ziqi Zhao, Caihong Sun, Jian Ma   +4 more
semanticscholar   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

Impact on hospitals of price reductions for physician-administered biologics. [PDF]

Health Aff Sch
Robinson JC, Thomson M, Kosorukov AD, Whaley CM.   +3 more
europepmc   +1 more source

Efficiency of Selected Risk Management Instruments - An Empirical Analysis of Risk Reduction in Kazakhstani Crop Production

Recent academic discussion regarding crop insurance in developing and transition countries has focused on weather index insurance. But empirical analyses of such schemes based on farm level data cannot be found in the literature, though this insurance ...
Heidelbach, Olaf
core  

Do drugs approved via expedited approval pathways have therapeutic advantages? A systematic review and meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Regulators use expedited approval pathways to speed market approval and patient access to promising new drugs. However, there is uncertainty about whether these pathways are successful in approving drugs with significant therapeutic advantages. This systematic review aims to examine the safety, effectiveness and cost‐effectiveness of drugs approved via
Ashleigh Hooimeyer, Eliza J. McEwin, Zhicheng Wang, Joel Lexchin, Barbara Mintzes   +4 more
wiley   +1 more source

A "Grounded in Health" Fair: Applying Environmental Health Approaches in a Cross-Specialty Community-Based Initiative. [PDF]

Environ Health Insights
Nwanaji-Enwerem U, Williams J, Forman R, Nwanaji-Enwerem JC.   +3 more
europepmc   +1 more source

The impacts of thresholds on risk behavior: What's wrong with index insurance?

Almost universally, implementers of index insurance for low income households have chosen to embed insurance with other interventions designed to improve productivity, with the insurance used almost entirely to make the other interventions possible.
Osgood, Daniel E., Shirley, Kenneth E.
core  

Impact of secured prescription implementation on ambulatory pregabalin use in France: A regional assessment in the French Nouvelle‐Aquitaine

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim The French authorities mandated the use of secure prescriptions for pregabalin on May 2021. This study aimed to evaluate the impact of this measure on pregabalin use and misuse in Nouvelle‐Aquitaine, a southwestern French region with around six million inhabitants.
Maika Munech‐Herran, Véronique Moysan, Bruno Lescarret, Clément Mathieu, Antoine Pariente, Nicolas Rousselot   +5 more
wiley   +1 more source